Difference between revisions of "Team:British Columbia/Human Practices"

m
m
Line 48: Line 48:
 
});
 
});
  
 +
.anchor{
 +
  height: 600px;
 +
}
  
 
</script>
 
</script>
Line 70: Line 73:
 
       <nav class="col-sm-3" id="side-menu">
 
       <nav class="col-sm-3" id="side-menu">
 
         <ul class="nav sidebar-nav nav-pills nav-stacked">
 
         <ul class="nav sidebar-nav nav-pills nav-stacked">
           <li class="active"><a href="#overview">Overview</a></li>
+
           <li class="active"><a href="#who-we-are">Who We Are</a></li>
           <li><a href="#s-layer">S-layer Engineering</a></li>
+
           <li><a href="#background">S-layer Engineering</a></li>
 
           <li><a href="#bio-pathways">Biosynthetic Pathways</a></li>
 
           <li><a href="#bio-pathways">Biosynthetic Pathways</a></li>
 
           <li><a href="#consortia">Consortia</a></li>
 
           <li><a href="#consortia">Consortia</a></li>

Revision as of 21:42, 16 October 2016

Main CSS Navbar CSS

Bootstrap Example

Human Practices

Overview

S-layer Engineering

The mesophilic organism Lysinibacillus sphaericus CCM 2177 produces the surface (S)-layer protein SbpA, which after secretion completely covers the cell surface with a crystalline array exhibiting square lattice symmetry. Because of its excellent in vitro recrystallization properties on solid supports, SbpA represents a suitable candidate for genetically engineering to create a versatile self-assembly system for the development of a molecular construction kit for nanobiotechnological applications. The first goal of this study was to investigate the surface location of 3 different C-terminal amino acid positions within the S-layer lattice formed by SbpA. Therefore, three derivatives of SbpA were constructed, in

Biosynthetic Pathways

Consortia